Sourcing cagrilintide for weight loss Obtaining this investigational peptide requires caution
Protocol 2: Intermediate approach (experienced researchers) Goal: Multi-target immune modulation with anti-inflammatory support Components: Thymosin alpha-1: 1.6 mg subcutaneously, three times weekly KPV: 200-500 mcg subcutaneously, once daily BPC-157: 250 mcg subcutaneously, twice daily Selank: 250-500 mcg intranasally, once daily Schedule: Monday, Wednesday, Friday: Thymosin alpha-1 Daily AM: KPV + BPC-157 Daily PM: BPC-157 Daily: Selank nasal spray (morning or midday) Duration: 12 weeks on, 4 weeks off Monitoring: Baseline labs, repeat every 4 weeks
It is a target for the acetaminophen metabolite AM404
Phase 2 CagriSema in T2D (Frias et al., 2023): CagriSema produced superior weight loss and glycemic improvement vs either monotherapy over 32 weeks
2000;352(Pt 1):2736
This is illustrated in the figure below, where the different colored circles represent amino acids in the crescent shaped enzyme